Pfizer INC 8-K filings

Pfizer reported robust second-quarter 2026 financial results, driven by strong performance in launched and acquired products, leading to an upward revision of its full-year revenue guidance.

Pfizer Inc. reaffirms its full-year 2026 financial guidance for revenues and adjusted diluted EPS following its Chief Financial Officer transition announcement.

Pfizer Inc. announced that Chief Financial Officer Dave Denton will depart on August 15, 2026, to pursue an opportunity in the consumer goods sector, with Cecile Guegan appointed as Interim CFO.

Pfizer Inc. announced robust first-quarter 2026 financial results, driven by a 22% operational revenue growth in launched and acquired products, and reaffirmed its full-year 2026 financial guidance.

Pfizer shareholders re-elected the board of directors and approved executive compensation at the 2026 Annual Meeting.

Pfizer Inc. announced its fourth-quarter and full-year 2025 financial results, reaffirming its full-year 2026 financial guidance and highlighting strong non-COVID portfolio growth.

Pfizer Inc. revised its full-year 2025 revenue guidance downwards while reaffirming EPS and providing full-year 2026 financial projections.

Pfizer Inc. completed a public offering of $6 billion in various debt securities, including floating and fixed-rate notes with maturities ranging from 2027 to 2065.

Pfizer Inc. has finalized its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion, including contingent value rights tied to key clinical and regulatory milestones.

Pfizer reported solid third-quarter 2025 financial results, raising and narrowing its full-year Adjusted diluted EPS guidance while reaffirming revenue guidance, and announced progress on key strategic initiatives including the Metsera acquisition and a landmark U.S. government agreement.

Pfizer Inc. reported strong second-quarter 2025 financial results, reaffirming revenue guidance while raising adjusted diluted EPS guidance, driven by commercial execution and R&D pipeline progress.

Pfizer Netherlands International Finance B.V. completes a public offering of euro-denominated notes guaranteed by Pfizer Inc., with maturities ranging from 2029 to 2045.

Pfizer announced its first-quarter 2025 financial results, reporting revenues of $13.7 billion and reaffirming its full-year 2025 financial guidance.

Pfizer held its annual shareholder meeting on April 24, 2025, where shareholders voted on the election of directors, ratification of the company's auditor, executive compensation, and other shareholder proposals.

Pfizer announces strong full-year 2024 results with $63.6 billion in revenues and reaffirms its 2025 financial guidance.

Pfizer has released its full-year 2025 financial guidance, projecting revenue between $61.0 and $64.0 billion and adjusted diluted EPS of $2.80 to $3.00, while also reaffirming its 2024 financial guidance.

Pfizer announced robust third-quarter 2024 results, driven by strong commercial execution and double-digit revenue growth, leading to an increase in full-year revenue and adjusted EPS guidance.

Pfizer has elected Mortimer J. Buckley, former CEO of Vanguard, to its Board of Directors, effective immediately.

Pfizer reported a 3% operational revenue increase in the second quarter of 2024, driven by non-COVID products, and raised its full-year revenue and adjusted EPS guidance.

Pfizer's Compensation Committee has approved modifications to outstanding Total Shareholder Return Units and Performance Share Awards granted in 2022 and 2023, offering employees the option to extend the terms of these awards.

Pfizer has begun the search for a new Chief Scientific Officer as Dr. Mikael Dolsten prepares to step down after a 15-year tenure.

Pfizer has elected Cyrus Taraporevala to its Board of Directors, effective immediately, and he will also join the Audit and Compensation Committees.

Pfizer is initiating a multi-year cost reduction program focused on operational efficiencies, network changes, and product portfolio enhancements, targeting $1.5 billion in savings by 2027.

Pfizer's first quarter results show a revenue decline due to decreased COVID-19 product sales, but strong growth in other areas and an increased adjusted EPS guidance.

Pfizer's annual shareholder meeting resulted in the election of directors, ratification of the accounting firm, and approval of the stock plan and executive compensation, while several shareholder proposals were not approved.

Pfizer's 2023 results were significantly impacted by a decline in COVID-19 product revenues, though non-COVID product growth and strategic acquisitions set the stage for future growth.